OPTIONS TRADES ARE A PRETTY GOOD TELL ON THE FUTURE OF A STOCK, IN THE CASE OF SNSS OPTIONS TRADED TODAY WERE OF INTEREST GIVEN THE FACT THE COMPANY WILL BE RELEASING DATA IN THE COMING DAYS. WITH A STRIKE PRICE OF $1 THEY PREDICT A UPSIDE POTENTIAL OF 40% BEFORE JUNE 21ST, THAT IS QUITE A NICE RISE FROM THE CURRENT LEVEL AND QUICK GAIN. SOMEONE KNOWS SOMETHING.
AVERAGE ANALYSTS PRICE TARGET $5.17
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
AVERAGE ANALYSTS PRICE TARGET $5.17
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media